Tigecycline has a broad antibacterial spectrum and is widely used for severely infected patient. Hypofibrinogenemia is a rare adverse reaction of tigecycline and scarcely reported. We present a case of 58-year-old woman who developed hypofibrinogenemia after tigecycline treatment, without other coagulation parameters changing. Moreover, hypofibrinogenemia reappeared when tigecycline was readministered, and fibrinogen concentration restored to normal level after withdrawing tigecycline. We found that hypofibrinogenemia was probably induced by tigecycline through assessing the causality by Naranjo adverse drug reaction probability scale. Therefore, our case raises concern about an adverse reaction of tigecycline-induced hypofibrinogenemia, especially for critically ill patients with high risk of coagulopathy. In conclusion, we suggest that fibrinogen should be monitored for patients with coagulopathy risk during tigecycline treatment, especially for critically ill patients.
HTML PDFShare this article
Journal of Clinical Case Reports received 1345 citations as per Google Scholar report
